Geriatric Medicine CME Courses

Credits: 13 (AMA PRA Category 1)
Format: Interactive Online
Price: $399
Credits: 1.5 (AMA PRA Category 1)
Format: Online Streaming Video
Price: $25/hour
Release Date: 11/1/2015
Expiration Date: 10/31/2017
Summary: Course Topics:
  • Ask questions in order to gather information on the patient's Explanatory Model, or understanding, of her illness experience.
  • Organize your approach to culture using the LEARN mnemonic: Listen, Explain, Acknowledge, Recommend, and Negotiate.
  • Understand and respond to patients' faith-based values and goals for care.
  • Allow patients to anticipate and consider aspects of the dying process they may not have considered.
  • Organize communication between others who are involved in patients' end-of-life care.
  • Incorporate patients' preferences and values in advance care planning.
  • Identify ways for answering requests from a patient's family that raise ethical questions.
  • Analyze the best way to offer truth in order to elicit patients' preferences.
  • Offer solutions that take patients' preferences into account as well as your ethical duty.
  • Weigh evidence for and against complementary and alternative medicine (CAM) practices.
  • Advise patients on the basis of evidence.
  • Work on treatment plans with patients who incorporate CAM.
  • Promote open communication in order to build trust with patients.
Credits: 1 (AMA PRA Category 1)
Format: Interactive Online
Price: Free
Release Date: 4/4/17
Expiration Date: 6/23/18


  • George T. Grossberg, MD Samuel W. Fordyce Professor; Director, Geriatric Psychiatry Department of Psychiatry and Behavioral Neuroscience, Saint Louis University School of Medicine
  • David Beck, MD Associate Professor, Department of Psychiatry and Behavioral Neuroscience, Saint Louis University School of Medicine

Topic and Learning Objectives

  • Identify different and various forms of agitation among patients with Alzheimer's disease (AD).
  • Review proposed mechanisms underlying agitation in AD and how pharmacologic agents may affect them
  • Evaluate body of evidence of current and emerging pharmacologic agents for the management of agitation/aggression in patients with AD